Gilead Sciences, Inc (NASDAQ: GILD) has experienced a rise in its stock price by 2.83 compared to its previous closing price of 107.62. However, the company has seen a gain of 2.00% in its stock price over the last five trading days. globenewswire.com reported 2025-06-28 that NEW YORK, June 28, 2025 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Gilead Sciences, Inc. (“Gilead” or the “Company”) (NASDAQ: GILD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Is It Worth Investing in Gilead Sciences, Inc (NASDAQ: GILD) Right Now?
Gilead Sciences, Inc (NASDAQ: GILD) has a price-to-earnings ratio of 23.27x that is above its average ratio. Additionally, the 36-month beta value for GILD is 0.30. There are mixed opinions on the stock, with 15 analysts rating it as a “buy,” 4 rating it as “overweight,” 11 rating it as “hold,” and 0 rating it as “sell.”
The public float for GILD is 1.24B and currently, short sellers hold a 1.85% ratio of that float. The average trading volume of GILD on June 30, 2025 was 9.06M shares.
GILD’s Market Performance
The stock of Gilead Sciences, Inc (GILD) has seen a 2.00% increase in the past week, with a 2.06% rise in the past month, and a -0.44% fall in the past quarter. The volatility ratio for the week is 2.91%, and the volatility levels for the past 30 days are at 2.67% for GILD. The simple moving average for the last 20 days is 1.18% for GILD’s stock, with a simple moving average of 12.43% for the last 200 days.
Analysts’ Opinion of GILD
Many brokerage firms have already submitted their reports for GILD stocks, with Cantor Fitzgerald repeating the rating for GILD by listing it as a “Overweight.” The predicted price for GILD in the upcoming period, according to Cantor Fitzgerald is $125 based on the research report published on April 22, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see GILD reach a price target of $132, previously predicting the price at $115. The rating they have provided for GILD stocks is “Outperform” according to the report published on March 04th, 2025.
Deutsche Bank gave a rating of “Buy” to GILD, setting the target price at $120 in the report published on February 18th of the current year.
GILD Trading at 4.14% from the 50-Day Moving Average
After a stumble in the market that brought GILD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.74% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GILD starting from Dickinson Andrew D, who sale 2,500 shares at the price of $110.17 back on Jun 16 ’25. After this action, Dickinson Andrew D now owns 165,110 shares of Gilead Sciences, Inc, valued at $275,425 using the latest closing price.
Mercier Johanna, the Chief Commercial Officer of Gilead Sciences, Inc, sale 3,000 shares at $110.17 during a trade that took place back on Jun 16 ’25, which means that Mercier Johanna is holding 120,168 shares at $330,510 based on the most recent closing price.
Stock Fundamentals for GILD
Current profitability levels for the company are sitting at:
- 0.29 for the present operating margin
- 0.78 for the gross margin
The net margin for Gilead Sciences, Inc stands at 0.21. The total capital return value is set at 0.19. Equity return is now at value 32.51, with 10.58 for asset returns.
Based on Gilead Sciences, Inc (GILD), the company’s capital structure generated 0.57 points at debt to capital in total, while cash flow to debt ratio is standing at 0.42. The debt to equity ratio resting at 1.3. The interest coverage ratio of the stock is 8.35.
Currently, EBITDA for the company is 4.43 billion with net debt to EBITDA at 1.61. When we switch over and look at the enterprise to sales, we see a ratio of 5.38. The receivables turnover for the company is 6.55for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In conclusion, Gilead Sciences, Inc (GILD) has seen better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
